Abstract Search

ea0033oc3.4 | Oral Communications 3 | BSPED2013

Successful Use of Long Acting Octreotide in Treatment of Congenital Hyperinsulinism

Shah Pratik , Gilbert Clare , Morgan Kate , Hinchey Louise , Senniappan Senthil , Arya Ved , Levy Hannah , Hussain Khalid

Introduction/Aim: Congenital hyperinsulinism (CHI) is a cause of severe hypoglycaemia in infancy. Treatment of diazoxide unresponsive patients includes the use of somatostatin analogues (octreotide given either as four s.c. injections daily or via a pump). We aimed to evaluate the use of a long acting somatostatin analogue (Lanreotide) in children with CHI, switching them from daily oral diazoxide or s.c. Octreotide injections to 4 weekly Lanreotide injections.<p class="ab...

0 shares

ea0039p4 | (1) | BSPED2015

Use of long acting somatostatin analogue (Lanreotide) in CHI – its pharmacokinetics and long-term follow-up study

Shah Pratik , Rahman Sofia , McElroy Sharon , Gilbert Clare , Morgan Kate , Hinchey Louise , Button Roberta , Margetts Rebecca , Senniappan Senthil , Guemes Maria , Levy Hannah , Morte Marti Carles , Celma Lezcano Carles , Amin Rakesh , Hussain Khalid

Background: CHI is a cause of severe hypoglycaemia in children. Diazoxide (KATP channel agonist) is used as first-line treatment but is known to cause severe hypertrichosis and reduced appetite in children. Diazoxide unresponsive CHI us treated with daily octreotide subcutaneous injections (34 times/day).Objective and hypotheses: To evaluate the efficacy, safety and pharmacokinetics of long acting Somatostatin analogue (Lanreotide) thera...

0 shares

ePoster

Endocrine Abstracts

Successful Use of Long Acting Octreotide in Treatment of Congenital Hyperinsulinism

Use of long acting somatostatin analogue (Lanreotide) in CHI – its pharmacokinetics and long-term follow-up study

BiosciAbstracts